17th Jun 2020 15:58
ReNeuron Group PLC - Bridgend, Wales-based stem cell research company - Receives regulatory approval from the US Food & Drug Administration and UK Medicines & Healthcare products Regulatory Agency for the expanded Phase 2a study in retinitis pigmentosa patients. To commence treating patients shortly in both the US and the UK under the revised approved study protocol, subject to a continued easing of Covid-19 related restrictions. Retinitis pigmentosa is a rare genetic disorders that involve a breakdown and loss of cells in the retina.
Current stock price: 135.22 pence
Year-to-date change: down 9%
By Tapan Panchal; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
RENE.L